Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.89 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.89 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.73 |
| ▸ | SMO | Q99835 | 3/20 | 0.71 |
| ▸ | MAPT | P10636 | 4/20 | 0.69 |
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | GFER | P55789 | 1/20 | 0.69 |
| ▸ | ATM | Q13315 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8021011 | 0.94 | MEN1 (1.00) | MEN1KMT2AABCB1SMOMAPT | |
| SCHEMBL1458094 | 0.88 | MEN1 (0.74) | MEN1KMT2AABCB1MAPTLMNA | |
| SCHEMBL15189215 | 0.87 | MEN1 (0.74) | MEN1KMT2AABCB1SMOMAPT | |
| SCHEMBL30958899 | 0.87 | ATM (0.89) | MEN1KMT2AABCB1SMOMAPT | |
| SCHEMBL27714560 | 0.87 | SMO (0.71) | MEN1KMT2AABCB1SMOMAPT | |
| SCHEMBL9497852 | 0.86 | ALDH1A1 (0.75) | MEN1KMT2AABCB1SMOMAPT | |
| SCHEMBL9190681 | 0.86 | ABCB1 (0.76) | MEN1KMT2AABCB1MAPTLMNA | |
| SCHEMBL12584908 | 0.86 | ABCB1 (0.76) | MEN1KMT2AABCB1MAPTLMNA | |
| Iodide SCHEMBL30758622 | 0.86 | ATM (0.86) | MEN1KMT2AABCB1SMOMAPT | |
| SCHEMBL8021017 | 0.86 | MEN1 (0.76) | MEN1KMT2AABCB1SMOMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1553075-B1 | LPA RECEPTOR ANTAGONISTS | ONO PHARMACEUTICAL CO (JP) | 2013-08-14 | — | — | EP | disclosed |
| EP-2565178-A1 | LPA Receptor Antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-20120088782-A1 | LPA RECEPTOR ANTAGONIST | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-04-12 | — | — | US | disclosed |
| US-8124645-B2 | LPA receptor antagonist | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-02-28 | — | — | US | disclosed |
| US-7820682-B2 | LPA receptor antagonist | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-10-26 | — | — | US | disclosed |
| US-20100249157-A2 | LPA RECEPTOR ANTAGONIST | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-1635839-B1 | BENZO[4,5]THIENO[2,3-D]PYRIMIDIN-4-ONES AND THEIR USE IN THERAPY | ABBOTT HEALTHCARE PRODUCTS BV (NL) | 2010-09-01 | — | — | EP | disclosed |
| US-7524853-B2 | Compounds and their use in therapy | SOLVAY PHARMACEUTICALS B.V. (NL) | 2009-04-28 | — | — | US | disclosed |
| US-7465739-B2 | Compounds and their use in therapy | SOLVAY PHARMACEUTICALS B.V. (NL) | 2008-12-16 | — | — | US | disclosed |
| US-20080293764-A1 | LPA RECEPTOR ANTAGONIST | ONO PHARMACEUTICAL CO., LTD. | 2008-11-27 | — | — | US | disclosed |
| US-20060148830-A1 | Lpa receptor antagonist | ONO PHARMACEUTICAL CO., LTD. | 2006-07-06 | — | — | US | disclosed |
| US-20050176742-A1 | Novel compounds and their use in therapy | SOLVAY PHARMACEUTICALS B.V. (NL) | 2005-08-11 | — | — | US | disclosed |
| EP-1553075-A1 | LPA RECEPTOR ANTAGONISTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-07-13 | — | — | EP | disclosed |
| US-20050038053-A1 | Novel compounds and their use in therapy | SOLVAY PHARMACEUTICALS B.V. (NL) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293764-A1 | LPA RECEPTOR ANTAGONIST | LPAR1, LPAR2, LPAR4 | MEN1 1200/4885KMT2A 933/4885ABCB1 2906/4885 |
| US-20100249157-A2 | LPA RECEPTOR ANTAGONIST | LPAR1, LPAR2, LPAR4 | MEN1 1200/4885KMT2A 933/4885ABCB1 2906/4885 |
| US-20120088782-A1 | LPA RECEPTOR ANTAGONIST | LPAR1, LPAR2, LPAR4 | MEN1 1200/4885KMT2A 933/4885ABCB1 2906/4885 |
| US-20050176742-A1 | Novel compounds and their use in therapy | HSD17B11, HSD17B2, HSD17B1 | MEN1 2028/4885KMT2A 2945/4885ABCB1 465/4885 |
| US-20050038053-A1 | Novel compounds and their use in therapy | HSD17B11, HSD17B2, HSD17B1 | MEN1 2028/4885KMT2A 2945/4885ABCB1 465/4885 |
| US-20060148830-A1 | Lpa receptor antagonist | LPAR1, LPAR2, LPAR4 | MEN1 1200/4885KMT2A 933/4885ABCB1 2906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.